Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012 AM1)

This study has been terminated.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT01440595
First received: September 22, 2011
Last updated: November 9, 2014
Last verified: November 2014
  Purpose

This study will evaluate the safety, tolerability, and antiviral activity of grazoprevir (MK-5172) when administered concomitantly with peginterferon alfa-2b (Peg-IFN) and ribavirin (RBV) to treatment-naïve participants with chronic genotype 2 (GT2) or genotype 3 (GT3) hepatitis C virus (HCV) infections.


Condition Intervention Phase
Hepatitis C, Chronic
Drug: Grazoprevir
Drug: Placebo to Grazoprevir
Drug: Peginterferon alfa-2b (Peg-IFN)
Drug: Ribavirin (RBV)
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Randomized, Partially Double-Blind, Active-Controlled, Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly With Pegylated-Interferon and Ribavirin in Treatment-Naive Patients With Chronic Genotype 2 or 3 Hepatitis C Virus Infection

Resource links provided by NLM:


Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • Number of participants achieving complete early virologic response (cEVR) in the grazoprevir treatment arms [ Time Frame: Week 12 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Time to first achievement of undetectable HCV ribonucleic acid (RNA) [ Time Frame: Baseline to Week 12 for Grazoprevir treatment arms, Week 24 for Placebo arm ] [ Designated as safety issue: No ]
  • Number of participants achieving rapid viral response (RVR) [ Time Frame: Week 4 ] [ Designated as safety issue: No ]
  • Number of participants achieving sustained viral response 12 weeks after completion of therapy (SVR12) [ Time Frame: Week 24 for Grazoprevir treatment arms, Week 36 for Placebo arm ] [ Designated as safety issue: No ]
  • Number of participants achieving sustained viral response 24 weeks after completion of therapy (SVR24) [ Time Frame: Week 36 for Grazoprevir treatment arms, Week 48 for Placebo arm ] [ Designated as safety issue: No ]
  • Number of participants achieving undetectable HCV RNA at Week 12 in the Placebo arm [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
  • Number of participants achieving complete early virologic response (cEVR) at Week 24 in the Placebo arm [ Time Frame: Week 24 ] [ Designated as safety issue: No ]

Enrollment: 5
Study Start Date: November 2011
Study Completion Date: May 2012
Primary Completion Date: May 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Grazoprevir 200 mg
Grazoprevir 200 mg in combination with Peg-IFN and RBV for 12 weeks
Drug: Grazoprevir
Grazoprevir once daily for 12 weeks
Drug: Peginterferon alfa-2b (Peg-IFN)
Peg-IFN weekly subcutaneous injection at 1.5 mcg/kg/week for 12 or 24 weeks
Other Name: PegIntron®, SCH 054031
Drug: Ribavirin (RBV)
Ribavirin twice daily at a dose of 600 mg to 1400 mg based on weight for 12 or 24 weeks
Other Name: Rebetol®, SCH 018908
Experimental: Grazoprevir 400 mg
Grazoprevir 400 mg in combination with Peg-IFN and RBV for 12 weeks
Drug: Grazoprevir
Grazoprevir once daily for 12 weeks
Drug: Peginterferon alfa-2b (Peg-IFN)
Peg-IFN weekly subcutaneous injection at 1.5 mcg/kg/week for 12 or 24 weeks
Other Name: PegIntron®, SCH 054031
Drug: Ribavirin (RBV)
Ribavirin twice daily at a dose of 600 mg to 1400 mg based on weight for 12 or 24 weeks
Other Name: Rebetol®, SCH 018908
Experimental: Grazoprevir 800 mg
Grazoprevir 800 mg in combination with Peg-IFN and RBV for 12 weeks
Drug: Grazoprevir
Grazoprevir once daily for 12 weeks
Drug: Peginterferon alfa-2b (Peg-IFN)
Peg-IFN weekly subcutaneous injection at 1.5 mcg/kg/week for 12 or 24 weeks
Other Name: PegIntron®, SCH 054031
Drug: Ribavirin (RBV)
Ribavirin twice daily at a dose of 600 mg to 1400 mg based on weight for 12 or 24 weeks
Other Name: Rebetol®, SCH 018908
Placebo Comparator: Placebo
Placebo to Grazoprevir in combination with Peg-IFN and RBV for 12 weeks, followed by open-label Peg-IFN and RBV for an additional 12 weeks
Drug: Placebo to Grazoprevir
Placebo to Grazoprevir once daily for 12 weeks
Drug: Peginterferon alfa-2b (Peg-IFN)
Peg-IFN weekly subcutaneous injection at 1.5 mcg/kg/week for 12 or 24 weeks
Other Name: PegIntron®, SCH 054031
Drug: Ribavirin (RBV)
Ribavirin twice daily at a dose of 600 mg to 1400 mg based on weight for 12 or 24 weeks
Other Name: Rebetol®, SCH 018908

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Body weight ≥ 88 lbs and ≤ 275 lbs
  • Documented CHC GT2 or GT3 infection
  • No known cirrhosis
  • Agrees to use two acceptable methods of birth control during study and through 6 months after last dose of study drug
  • Chest X-ray within the last 6 months
  • Eye exam within the last 6 months

Exclusion Criteria:

  • Known to be human immunodeficiency virus (HIV) positive or co-infected with active hepatitis B virus (positive for Hepatitis B surface antigen)
  • Prior approved or investigational treatment for hepatitis C
  • Evidence of hepatocellular carcinoma
  • Diabetic and/or high blood pressure with clinically significant eye exam findings
  • Pre-existing psychiatric condition
  • Clinical diagnosis of abuse of certain substances within specified timeframes
  • Known medical condition that could interfere with participation
  • Active or suspected cancer within the last 5 years
  • Female who is pregnant, breastfeeding, or expecting to conceive or donate eggs
  • Male who is planning to impregnate partner or donate sperm
  • Male with a pregnant female partner
  • Chronic hepatitis not caused by HCV
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT01440595     History of Changes
Other Study ID Numbers: 5172-012
Study First Received: September 22, 2011
Last Updated: November 9, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Hepatitis
Hepatitis A
Hepatitis C
Hepatitis C, Chronic
Digestive System Diseases
Enterovirus Infections
Flaviviridae Infections
Hepatitis, Chronic
Hepatitis, Viral, Human
Liver Diseases
Picornaviridae Infections
RNA Virus Infections
Virus Diseases
Peginterferon alfa-2b
Ribavirin
Anti-Infective Agents
Antimetabolites
Antiviral Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on November 24, 2014